OAB-047: Plasma cell disorder patients are left vulnerable after one dose of the BNT162b2 mRNA or the ChAdOx-nCOV-19 COVID-19 vaccines

BACKGROUND: Concerns have been raised about the ability of patients with plasma cell disorders (PCD) to mount adequate immune responses to vaccination, particularly considering the initial extension to vaccination intervals in the United Kingdom to up to 12 weeks in December 2020, the start of the v...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Wei Yee, Howells, Lara, Wilson, William, Sanchez, Emilie, Ainley, Louise, Chavda, Selina, Dowling, Emma, Correia, Nuno, Lecat, Catherine, McMillan, Annabel, Wisniowski, Brendan, Mahmood, Shameem, Papanikolaou, Xenofon, Lee, Lydia, Sive, Jonathan, Kyriakou, Charalampia, Wechalekar, Ashutosh, Popat, Rakesh, Rabin, Neil, Nastouli, Eleni, Yong, Kwee, Xu, Ke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Oral Presentations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580184/
http://dx.doi.org/10.1016/S2152-2650(21)02121-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580184/
http://dx.doi.org/10.1016/S2152-2650(21)02121-2

Ejemplares similares